Every round on record, with the sources behind each and the investors on them.
No description yet.
eviabio.comMinneapolis, MN
2 sources · checked 1 time, last 9d ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The company's release announces the Series A on September 16, 2026 but states no amount, valuation, or investors; the SEC filing supplies no additional round details.
Publication audit: announced 2026-09-16: "MINNEAPOLIS, MN – September 16, 2026 – Evia Bio, Inc., a life science company advancing next-generation cryopreservation technologies for cell therapy, announced the closing of its Series A financing round." (https://eviabio.com/evia-bio-closes-series-a-financing)
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A | n/a | 2026-09-16 | not stated | No recent discussion |
2 sources · checked 1 time, last 9d ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 2 sources
The company's release announces the Series A on September 16, 2026 but states no amount, valuation, or investors; the SEC filing supplies no additional round details. Publication audit: announced 2026-09-16: "MINNEAPOLIS, MN – September 16, 2026 – Evia Bio, Inc., a life science company advancing next-generation cryopreservation technologies for cell therapy, announced the closing of its Series A financing round." (https://eviabio.com/evia-bio-closes-series-a-financing) [ BUILT WITH ]·[ SEARCH ]found while cross-checking another source·[ SCRAPE ]2 pages read: eviabio.com, sec.gov·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 2 sources·[ AGENT ]company research by the Firecrawl agent | ||||
Evia Bio builds DMSO-free cryopreservation products and services for cell-therapy companies moving therapies toward clinical trials and commercialization.
Evia Bio says conventional DMSO cryopreservation can damage cells and cause adverse reactions for patients, while its natural-osmolyte, DMSO-free approach is intended to improve post-thaw cell performance and safety. The company says its latest Series A financing will fund product development, commercial expansion, and customer partnerships after launching its first MSC media in Q4 2025 and planning additional T-cell and CAR-T products.
Checked against 10 sources on Sep 28
None named.
Also named as backers in company research: MN Cup, Minnesota Innovation Corps (MIN-Corps), University of Minnesota